Maria Constance Athanasiou
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$5.4MFederal grants as PI11 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $5.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Feb 13, 2025 | NIH | STTR Phase II A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | $979K | MARPAM PHARMA, LLC |
| Mar 14, 2024 | NIH | STTR Phase I Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV | $302K | MARPAM PHARMA, LLC |
| Feb 12, 2024 | NIH | STTR Phase II A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | $1.0M | MARPAM PHARMA, LLC |
| Feb 22, 2023 | NIH | STTR Phase II A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | $55K | MARPAM PHARMA, LLC |
| Dec 7, 2022 | NIH | STTR Phase I Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells | $307K | MARPAM PHARMA, LLC |
| Nov 22, 2022 | NIH | STTR Phase II Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | $119K | MARPAM PHARMA, LLC |
| Aug 3, 2022 | NIH | STTR Phase II Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | $1.0M | MARPAM PHARMA, LLC |
| Jul 5, 2022 | NIH | STTR Phase II A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | $300K | MARPAM PHARMA, LLC |
| Aug 9, 2021 | NIH | STTR Phase II Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | $1.0M | MARPAM PHARMA, LLC |
| Feb 18, 2021 | NIH | STTR Phase I Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | $52K | MARPAM PHARMA, LLC |
| Jun 18, 2020 | NIH | STTR Phase I Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | $300K | MARPAM PHARMA, LLC |
Peer ranks
Federal funding#236
Awards as PI#106
Patents#273
Companies
- MARPAM PHARMA, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.